Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jose Baselga

Showing results (11-20 of 126) with videos related to

Pageof 13
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2003
Status of epidermal growth factor receptor antagonists in the biology and treatment of cancerJohn Mendelsohn, Jose Baselga
Cancer Chemotherapy and Biological Response Modifiers|August 23, 2005
Epidermal growth factor receptor pathway inhibitorsJose Baselga, Javier Cortes
Seminars in Oncology|August 8, 2006
Epidermal growth factor receptor targeting in cancerJohn Mendelsohn, Jose Baselga
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2003
Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practiceCarlos L Arteaga, Jose Baselga
Cancer Cell|June 15, 2004
Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them?Carlos L Arteaga, Jose Baselga
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2010
Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancerSteven J Isakoff, Jose Baselga
Cell Cycle (Georgetown, Tex.)|December 23, 2008
Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitorsArkaitz Carracedo, Jose Baselga, Pier Paolo Pandolfi
Cell|April 5, 2011
The evolving war on cancerDaniel A Haber, Nathanael S Gray, Jose Baselga
European Journal of Cancer (Oxford, England : 1990)|November 21, 2002
The future of breast cancer research in dangerMichael Baum, Mary Buchanan, Jose Baselga, et al.
Cancer|May 17, 2008
Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapiesJan B Vermorken, Roy S Herbst, Xavier Leon, et al.
Pageof 13

Showing results (11-20 of 126) with videos related to

Sort By:
Pageof 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2003
Status of epidermal growth factor receptor antagonists in the biology and treatment of cancerJohn Mendelsohn, Jose Baselga
Cancer Chemotherapy and Biological Response Modifiers|August 23, 2005
Epidermal growth factor receptor pathway inhibitorsJose Baselga, Javier Cortes
Seminars in Oncology|August 8, 2006
Epidermal growth factor receptor targeting in cancerJohn Mendelsohn, Jose Baselga
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2003
Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practiceCarlos L Arteaga, Jose Baselga
Cancer Cell|June 15, 2004
Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them?Carlos L Arteaga, Jose Baselga
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2010
Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancerSteven J Isakoff, Jose Baselga
Cell Cycle (Georgetown, Tex.)|December 23, 2008
Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitorsArkaitz Carracedo, Jose Baselga, Pier Paolo Pandolfi
Cell|April 5, 2011
The evolving war on cancerDaniel A Haber, Nathanael S Gray, Jose Baselga
European Journal of Cancer (Oxford, England : 1990)|November 21, 2002
The future of breast cancer research in dangerMichael Baum, Mary Buchanan, Jose Baselga, et al.
Cancer|May 17, 2008
Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapiesJan B Vermorken, Roy S Herbst, Xavier Leon, et al.
Pageof 13